The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

September 1, 2024

Conditions
Prostate InflammationProstate DiseaseChronic Bacterial Prostatitis
Interventions
DRUG

Sodium Hyaluronate

Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.

DRUG

Levofloxacin 500mg

Treatment typically involves fluoroquinolones alone, such as levofloxacin.

Trial Locations (1)

80131

University of Naples Federico II, Napoli

All Listed Sponsors
lead

Federico II University

OTHER

NCT06684626 - The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment | Biotech Hunter | Biotech Hunter